tradingkey.logo
tradingkey.logo
Suchen

BioLife Solutions Inc

BLFS
Zur Watchlist hinzufügen
28.110USD
-0.380-1.33%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
1.37BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über BioLife Solutions Inc Unternehmen

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

BioLife Solutions Inc Informationen

BörsenkürzelBLFS
Name des UnternehmensBioLife Solutions Inc
IPO-datumNov 22, 1989
CEODe Greef (Roderick)
Anzahl der mitarbeiter159
WertpapierartOrdinary Share
GeschäftsjahresendeNov 22
AddresseSuite 310
StadtBOTHELL
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl98021
Telefon14254011400
Websitehttps://www.biolifesolutions.com/
BörsenkürzelBLFS
IPO-datumNov 22, 1989
CEODe Greef (Roderick)

Führungskräfte von BioLife Solutions Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
292.78K
-0.41%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
132.07K
-1.49%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
66.03K
-154.97%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
65.47K
-1.76%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
47.83K
-0.88%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
44.99K
-2.88%
Ms. Catherine (Cathy) Coste, CPA
Ms. Catherine (Cathy) Coste, CPA
Independent Director
Independent Director
5.70K
-143.31%
Mr. Roderick De Greef
Mr. Roderick De Greef
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd Berard
Mr. Todd Berard
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Amy Duross
Ms. Amy Duross
Lead Independent Director
Lead Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
292.78K
-0.41%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
132.07K
-1.49%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
66.03K
-154.97%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
65.47K
-1.76%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
47.83K
-0.88%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
44.99K
-2.88%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von BioLife Solutions Inc?

Die fünf größten Anteilseigner von BioLife Solutions Inc sind: Dr. Aby J. Mathew, Ph.D.

Wie viele Institutionen halten Anteile an BioLife Solutions Inc (BLFS)?

Mit Stand vom 2026Q1 halten 430 Institutionen Anteile an BioLife Solutions Inc, mit einem Gesamtmarktwert von etwa 51.34M, was 105.07% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1261408.00 gestiegen.